

ORGANIC CHEMISTRY

FRONTIERS

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Generation of 1-amino-isoquinoline-*N*-oxides via a tandem reaction of 2-alkynylbenzaldoxime with secondary amines in the presence of silver(I) and copper(I)

Junjie Song,^a Congbin Fan,^a Gang Liu,^{*a} and Guanyinsheng Qiu^{*b}⁵ Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX

DOI: 10.1039/b000000x


1-Amino-isoquinoline-*N*-oxides are generated under mild conditions through a tandem reaction of 2-alkynylbenzaldoxime with secondary amines in the presence of a silver(I) and copper(I). The reaction proceeds smoothly at room temperature under air, leading to the corresponding products in good yields. During the reaction process, a silver-catalyzed 6-endo cyclization and a copper(I)-catalyzed C-H bond activation are involved.

1. Introduction

In the past decade, the achievement for the diversity-oriented synthesis of natural product-like compounds with privileged scaffolds has been witnessed.¹ A range of *N*-heterocycles has been applied broadly in the drug discovery process. We also involved in the libraries construction of small molecules with privileged scaffolds.² Some hits have been identified during the subsequent biological assays. For instance, 2-alkynylbenzaldoxime as a versatile building block has been applied widely for the construction of *N*-heterocycles.³ Since it could be easily transferred to isoquinoline *N*-oxide via intramolecular 6-endo cyclization in the presence of metal catalysts or electrophiles,⁴ the subsequent [3+2] cycloaddition/nucleophilic addition and rearrangement could be expected. On the other hand, a Beckmann rearrangement could be happened first since an oxime moiety is present in the molecule, which would then undergo an intramolecular cyclization to furnish nitrogen-containing heterocycles.⁵ Therefore, 2-alkynylbenzaldoxime is recognized as a good candidate for the generation of small molecules' libraries. In most cases, the chemistry is related to isoquinoline *N*-oxide, which could be isolated and obtained from 2-alkynylbenzaldoxime via 6-endo cyclization. A large collection of small molecules would be produced if diverse isoquinoline *N*-oxides could be easily accessible.

Recently, transition metal catalyzed direct C-H oxidative amination of arenes has attracted much attention.⁶ For instance, Wu and Cui reported a copper(I)-catalyzed reaction of quinoline-*N*-oxide with amines.^{6a} During the process, the C-H bond at the *ortho*-position of *N*-oxide was activated, thus undergoing the subsequent amination. Encouraged by this result, we envisioned that the C-H bond at the *ortho*-position of isoquinoline *N*-oxide

could be activated as well, which would react with amines to provide diverse 1-amino-isoquinoline-*N*-oxides. The proposed synthetic route is present in Scheme 1. We conceived that in the presence of silver(I) and copper(I) salts as co-catalysts, the reaction of 2-alkynylbenzaldoxime **1** with amines **2** would produce the corresponding 1-amino-isoquinoline-*N*-oxides. During the transformation, a silver(I)-catalyzed 6-endo cyclization would occur first to afford isoquinoline *N*-oxide **A**. Subsequently, a C-H bond activation would take place in the presence of copper(I) salt to form intermediate **B**. If the reaction was performed under air atmosphere, the oxygen would act as an oxidant to involve in the transformation with amines, leading to



Scheme 1 A proposed synthetic route to 1-amino-isoquinoline-*N*-oxides

intermediate **C** with the release of a molecular water. Following by reductive elimination would deliver 1-amino-isoquinoline-*N*-oxides **3**. With the consideration in mind, we thus initiated a program for the generation of 1-amino-isoquinoline-*N*-oxides.

2. Results and discussion

At the outset, the studies were initially performed for a model reaction of 2-alkynylbenzaldoxime **1a** with piperidine **2a** at 50 °C in toluene under air atmosphere (Table 1). A control experiment catalyzed by 10 mol % of silver triflate without the addition of copper(I) salt indicated that no desired product **3a** was formed (Table 1, entry 1). Only isoquinoline-*N*-oxide **A1** was isolated. This result demonstrated the important role of copper(I) catalyst in the reaction process for the activation of C-H bond at the *ortho*-position of isoquinoline *N*-oxide. As expected, 1-amino-





Figure 1 X-ray ORTEP illustration of compound **3a**

isoquinoline-*N*-oxide **3a** was obtained in 87% yield when Cu₂O (5 mol %) was added in the reaction system (Table 1, entry 2). The structure of **3a** was confirmed by the X-ray crystallographic analysis in the meantime (Figure 1). A similar result was observed when the copper salt was changed to CuCl or CuBr (Table 1, entries 3 and 4). The reaction co-catalyzed by silver triflate and palladium acetate gave rise to the expected product **3a** in 17% yield (data not shown in Table 1). Gratifyingly, the corresponding product **3a** was furnished in 95% yield when

Table 1 Initial studies for the reaction of 2-alkynylbenzaloxime **1a** with piperidine **2a**



Entry	[Cu]	Temp (°C)	Solvent	Yield (%) ^a
1	-	50	toluene	nr
2	Cu ₂ O	50	toluene	87
3	CuCl	50	toluene	85
4	CuBr	50	toluene	88
5	CuI	50	toluene	95
6	CuI	50	DCE	82
7	CuI	50	MeCN	79
8	CuI	50	1,4-dioxane	83
9	CuI	50	THF	80
10	CuI	50	DMA	76
11	CuI	25	toluene	96
12	CuI	80	toluene	95
13 ^b	CuI	25	toluene	21

^a Isolated yield based on 2-alkynylbenzaloxime **1a**;


^b In the absence of AgOTf

copper(I) iodide was used as the catalyst (Table 1, entry 5). No better yields were isolated when other solvents were utilized (Table 1, entries 6-10). The efficiency was not affected when the reaction occurred at room temperature (Table 1, entry 11). The

same result was observed when the reaction was performed at 15 80 °C (Table 1, entry 12).

The above mild optimized conditions prompted us to explore the scope of this silver(I) and copper(I) co-catalyzed reaction of 2-alkynylbenzaloximes **1** with amines **2**. The results are summarized in Table 2 and Table 3. At the beginning, reactions 20 of 2-alkynylbenzaloximes **1** with piperidine **2a** were examined (Table 2). It was found that in most cases, the reactions worked well to afford the expected products **3** in good to excellent yields. 2-Alkynylbenzaloximes **1** with different groups attached on the aromatic ring were all good reactants under the standard 25 conditions. Reactions of 2-alkynylbenzaloximes **1** with aryl groups attached on the triple bond (R²) proceeded smoothly,

Table 2 Synthesis of 1-amino-isoquinoline-*N*-oxides **3** through a silver(I) and copper(I) co-catalyzed reaction of 2-alkynylbenzaloxime **1** with piperidine **2a**^a




^a Isolated yield based on 2-alkynylbenzaloxime **1**.

leading to the corresponding products in good yields. Inferior results were obtained for the reaction of 2-alkynylbenzaloximes **1** with alkyl groups attached on the triple bond (compounds **3e** and **3f**).

We next investigated the silver(I) and copper(I) co-catalyzed reaction of 2-alkynylbenzaloxime **1a** with various amines (Table 3). Not only pyrrolidine but also azepane was a good partner in this transformation. Reaction of 2-alkynylbenzaloxime **1a** with 35 morpholine gave rise to the expected product **3n** in 93% yield. However, reaction of 2-alkynylbenzaloxime **1a** with 2,2,6,6-tetramethylpiperidine did not afford the desired product **3o**. From these results, it showed that the outcome was affected by the steric hinderance of substrates. Other acyclic amines such as 40 diethyl amine and dihexyl amine were employed in the reaction, which afforded a trace amount of the desired products. Moreover, primary amines are also not effective under the conditions (data not shown in Table 3), and no expected products **3** were detected

Table 3 Synthesis of 1-amino-isoquinoline-*N*-oxides **3** through a silver(I) and copper(I) co-catalyzed reaction of 2-alkynylbenzaloxime **1a** with secondary amines **2**^a



^a Isolated yield based on 2-alkynylbenzaloxime **1a**

when primary amines were used as reaction partners under the conditions.

3. Conclusion

In conclusion, we have reported the synthesis of 1-amino-isoquinoline-*N*-oxides through a silver(I) and copper(I) co-catalyzed reaction of 2-alkynylbenzaloxime with secondary amines under mild conditions. The transformation proceeds smoothly at room temperature under air, leading to the corresponding products in good yields. During the reaction process, a silver-catalyzed 6-*endo* cyclization and a copper(I)-catalyzed C-H bond activation are involved. The reaction scope has been demonstrated and a range of 1-amino-isoquinoline-*N*-oxides is produced efficiently. Currently, application of the 1-amino-isoquinoline-*N*-oxides for the construction of diverse *N*-heterocycles is ongoing in our laboratory.

4. Experimental Section

General experimental procedure for the synthesis of 1-amino-isoquinoline-*N*-oxides **3** through a silver(I) and copper(I) co-catalyzed reaction of 2-alkynylbenzaloximes **1** with amines **2**: A mixture of silver triflate (0.02 mmol, 5.1 mg) and 2-alkynylbenzaloxime **1** (0.2 mmol) in toluene (1.0 mL) was stirred at 70 °C for 1 hour. Then secondary amine **2** (1.6 mmol), CuI (0.01 mmol, 1.9 mg), and toluene (1.0 mL) were added subsequently. The reaction was stirred at 25 °C until completion of the reaction as indicated by TLC. The solvent was evaporated and the residue was purified by column chromatography on silica gel to provide the product **3**.

3-Phenyl-1-(trifluoromethyl)isoquinoline **3a**: ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 8.2 Hz, 1H), 7.75 - 7.70 (m, 3H), 7.61 - 7.49 (m, 3H), 7.49 - 7.38 (m, 3H), 3.79 (s, 2H), 3.17 (s, 2H), 1.83 - 1.75 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 151.1, 147.5, 133.8, 130.2, 129.9, 128.9, 128.2, 128.0, 127.5, 127.3,

126.9, 124.2, 120.8, 49.7, 26.6, 24.4; HRMS (ESI) calcd for C₂₀H₂₀N₂O: 305.1648 (M + H⁺), found: 305.166.

5-Methoxy-3-phenyl-1-(piperidin-1-yl)isoquinoline 2-oxide **3b**: ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H), 7.77 - 7.74 (m, 3H), 7.48 - 7.38 (m, 4H), 6.86 (d, *J* = 7.7 Hz, 1H), 3.97 (s, 3H), 3.72 (s, 2H), 3.16 (s, 2H), 1.79 - 1.75 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 155.2, 150.9, 146.6, 134.2, 130.9, 129.9, 128.7, 128.6, 127.9, 122.3, 116.2, 115.6, 106.4, 55.7, 49.6, 26.5, 24.4; HRMS (ESI) calcd for C₂₁H₂₂N₂O₂: 335.1754 (M + H⁺), found: 335.1758.

7-Chloro-3-phenyl-1-(piperidin-1-yl)isoquinoline 2-oxide **3c**: ¹H NMR (400 MHz, CDCl₃) δ 8.15 (s, 1H), 7.72 (dd, *J* = 8.0, 1.6 Hz, 2H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.51 (s, 1H), 7.48 - 7.40 (m, 4H), 3.80 (s, 2H), 3.09 (s, 2H), 1.85 - 1.75 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 150.5, 147.9, 134.3, 133.4, 130.9, 129.7, 129.1, 128.9, 128.5, 128.2, 128.1, 123.0, 120.6, 49.3, 26.5, 24.3; HRMS (ESI) calcd for C₂₀H₁₉ClN₂O: 339.1259 (M + H⁺), found: 339.1256.

7-Fluoro-3-phenyl-1-(piperidin-1-yl)isoquinoline 2-oxide **3d**: ¹H NMR (400 MHz, CDCl₃) δ 7.81 (dd, *J* = 10.3, 2.0 Hz, 1H), 7.73 - 7.70 (m, 3H), 7.54 (s, 1H), 7.48 - 7.40 (m, 3H), 7.31 - 7.26 (m, 1H), 3.78 (s, 2H), 3.08 (s, 2H), 1.84 - 1.75 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 162.2 (d, ¹*J*_{CF} = 247.4 Hz), 150.7, 147.1, 133.5, 130.9, 129.8, 129.0, 128.8, 128.1, 127.0, 120.7, 118.2 (d, ²*J*_{CF} = 25.4 Hz), 108.1 (d, ²*J*_{CF} = 24.0 Hz), 49.2, 26.5, 24.3; HRMS (ESI) calcd for C₂₀H₁₉FN₂O: 323.1554 (M + H⁺), found: 323.1561.

3-Butyl-1-(piperidin-1-yl)isoquinoline 2-oxide **3e**: ¹H NMR (400 MHz, CDCl₃) δ 8.14 - 8.12 (m, 1H), 7.66 - 7.64 (m, 1H), 7.50 - 7.48 (m, 2H), 7.33 (s, 1H), 3.75 (s, 2H), 3.10 (s, 1H), 3.03 - 2.95 (m, 2H), 2.17 (s, 1H), 1.78 - 1.72 (m, 8H), 1.54 - 1.45 (m, 2H), 0.99 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 150.8, 149.8, 130.2, 128.0, 127.3, 126.2, 124.1, 117.9, 49.6, 30.4, 29.2, 26.6, 24.3, 22.7, 13.9; HRMS (ESI) calcd for C₁₈H₂₄N₂O: 285.1961 (M + H⁺), found: 285.1952.

3-(*tert*-Butyl)-1-(piperidin-1-yl)isoquinoline 2-oxide **3f**: ¹H NMR (400 MHz, CDCl₃) δ 8.11 (d, *J* = 8.1 Hz, 1H), 7.66 (d, *J* = 7.7 Hz, 1H), 7.51 - 7.43 (m, 3H), 3.63 (s, 2H), 3.11 (s, 2H), 1.84 - 1.75 (m, 6H), 1.59 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 155.5, 151.9, 129.6, 127.5, 126.7, 123.5, 117.2, 49.1, 36.6, 28.3, 26.5, 24.3; HRMS (ESI) calcd for C₁₈H₂₄N₂O: 285.1961 (M + H⁺), found: 285.1941.

7-Methyl-3-phenyl-1-(piperidin-1-yl)isoquinoline 2-oxide **3g**: ¹H NMR (400 MHz, CDCl₃) δ 7.95 (s, 1H), 7.74 (d, *J* = 6.7 Hz, 2H), 7.62 (d, *J* = 7.9 Hz, 1H), 7.48 - 7.40 (m, 4H), 7.36 (d, *J* = 8.1 Hz, 1H), 3.74 (s, 2H), 3.14 (s, 2H), 2.56 (s, 3H), 1.81 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 150.8, 146.6, 138.3, 133.9, 130.9, 130.4, 129.8, 128.7, 127.9, 127.4, 126.8, 123.1, 120.7, 49.4, 26.5, 24.3, 22.2; HRMS (ESI) calcd for C₂₁H₂₂N₂O: 319.1805 (M + H⁺), found: 319.1802.

6-Fluoro-3-phenyl-1-(piperidin-1-yl)isoquinoline 2-oxide **3h**: ¹H NMR (400 MHz, CDCl₃) δ 8.19 (m, 1H), 7.73 (d, *J* = 6.6 Hz, 2H), 7.48 - 7.41 (m, 4H), 7.33 - 7.29 (m, 2H), 3.72 (s, 2H), 3.13 (s, 2H), 1.71 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 162.1 (d, ¹*J*_{CF} = 249.6 Hz), 151.2, 148.6, 133.5, 131.3, 129.7, 129.1, 128.0, 127.3 (d, ³*J*_{CF} = 8.9 Hz), 124.4, 120.1 (d, ⁴*J*_{CF} = 5.0 Hz), 118.3 (d, ²*J*_{CF} = 24.9 Hz), 110.9 (d, ²*J*_{CF} = 21.7 Hz), 49.5, 26.5, 24.3; HRMS (ESI) calcd for C₂₀H₁₉FN₂O: 323.1554 (M + H⁺), found: 323.1557.

3-(4-Chlorophenyl)-1-(piperidin-1-yl)isoquinoline 2-oxide **3i**: ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 8.3 Hz, 1H), 7.72 - 7.69 (m, 3H), 7.60 - 7.50 (m, 3H), 7.42 (d, *J* = 8.5 Hz, 2H), 3.73 (s, 2H), 3.19 (s, 2H), 1.85 - 1.75 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 151.2, 146.2, 134.9, 132.2, 131.2, 130.2, 128.4, 128.3, 127.3, 126.9, 124.2, 120.7, 49.6, 26.5, 24.3; HRMS (ESI) calcd for C₂₀H₁₉ClN₂O: 339.1259 (M + H⁺), found: 339.1258.

3-(4-Fluorophenyl)-1-(piperidin-1-yl)isoquinoline 2-oxide **3j**: ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.1 Hz, 1H), 7.76 - 7.70 (m, 3H), 7.59 - 7.50 (m, 3H), 7.13 (t, *J* = 8.4 Hz, 2H), 3.73 (s, 2H), 3.19 (s, 2H), 1.80 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 163.1 (d, ¹*J*_{CF} = 247.3 Hz), 151.2, 146.4, 131.9 (d, ³*J*_{CF} = 8.2 Hz), 130.2, 129.8, 128.3 (d, ³*J*_{CF} = 7.7 Hz), 127.2, 126.9, 124.2, 120.7, 115.0 (d, ²*J*_{CF} = 21.6 Hz), 49.6, 26.5, 24.3; HRMS (ESI) calcd for C₂₀H₁₉FN₂O: 323.1554 (M + H⁺), found: 323.1543.

3-(4-Methoxyphenyl)-1-(piperidin-1-yl)isoquinoline 2-oxide **3k**: ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 8.1 Hz, 1H), 7.73 - 7.68 (m, 3H), 7.59 - 7.48 (m, 3H), 6.98 (d, *J* = 8.8 Hz, 2H), 3.85 (s, 3H), 3.73 (s, 2H), 3.17 (s, 2H), 1.84 - 1.75 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 160.1, 151.1, 147.2, 131.3, 130.3, 128.1, 127.9, 127.0, 126.7, 126.1, 124.1, 120.4, 113.4, 55.4, 49.5, 26.6, 24.3; HRMS (ESI) calcd for C₂₁H₂₂N₂O₂: 335.1754 (M + H⁺), found: 335.1753.

3-Phenyl-1-(pyrrolidin-1-yl)isoquinoline 2-oxide **3l**: ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.2 Hz, 1H), 7.75 - 7.71 (m, 3H), 7.57 - 7.52 (m, 3H), 7.50 - 7.41 (m, 3H), 3.64 - 3.52 (m, 4H),

2.15 - 2.05 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 149.7, 147.6, 133.9, 130.9, 129.9, 129.8, 128.9, 128.6, 128.2, 128.1, 126.7, 124.7, 120.9, 48.8, 26.5; HRMS (ESI) calcd for C₁₉H₁₈N₂O: 291.1492 (M + H⁺), found: 291.1492.

1-(Azepan-1-yl)-3-phenylisoquinoline 2-oxide **3m**: ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 8.3 Hz, 1H), 7.76 - 7.72 (m, 3H), 7.60 - 7.57 (m, 2H), 7.54 - 7.50 (m, 1H), 7.48 - 7.40 (m, 3H), 3.43 (s, 4H), 1.83 (s, 8H); ¹³C NMR (100 MHz, CDCl₃) δ 152.5, 147.6, 133.7, 130.9, 130.1, 129.8, 128.9, 128.4, 128.2, 128.0, 126.8, 124.4, 121.4, 51.1, 30.5, 28.2; HRMS (ESI) calcd for C₂₁H₂₂N₂O: 319.1805 (M + H⁺), found: 319.1803.

1-Morpholino-3-phenylisoquinoline 2-oxide **3n**: ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 8.3 Hz, 1H), 7.75 - 7.72 (m, 3H), 7.61 - 7.54 (m, 3H), 7.50 - 7.43 (m, 3H), 3.96 (s, 8H); ¹³C NMR (100 MHz, CDCl₃) δ 149.5, 147.5, 133.5, 130.9, 130.2, 129.7, 129.0, 128.5, 128.4, 128.1, 127.1, 123.8, 121.3, 67.9, 48.5; HRMS (ESI) calcd for C₁₉H₁₈N₂O₂: 307.1441 (M + H⁺), found: 307.1447.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (21172038, 21372046, 21262015), the Science Funds of Natural Science Foundation of Jiangxi Province (20122BAB203005), and the Project of the Science Funds of Jiangxi Education Office (KJLD13069).

Notes and references

- ^a Jiangxi Key Laboratory of Organic Chemistry, Jiangxi Science & Technology Normal University, Nanchang 330013, China. E-mail: liugang0926@163.com
- ^b College of Biological, Chemical Science and Engineering, Jiaying University, 118 Jiahang Road, Jiaying 314001, China. E-mail: 11110220028@jdan.edu.cn
- † Author Contributions: J. Song and C. Fan contributed equally.
- Electronic Supplementary Information (ESI) available: [Experimental procedure, characterization data, ¹H and ¹³C NMR spectra of compounds **3**, the CIF file of compound **3a**.]. See DOI: 10.1039/b000000x/
- (a) D. P. Walsh and Y.-T. Chang, *Chem. Rev.* 2006, **106**, 2476. (b) P. Arya, D. T. H. Chou and M.-G. Baek, *Angew. Chem. Int. Ed.* 2001, **40**, 339. (c) S. L. Schreiber, *Science* 2000, **287**, 1964. (d) M. D. Burke and S. L. Schreiber, *Angew. Chem., Int. Ed.* 2004, **43**, 46. (e) S. L. Schreiber, *Nature* 2009, **457**, 153. (f) D. S. Tan, *Nat. Chem. Biol.* 2005, **1**, 74. (g) C. Cordier, D. Morton, S. Murrison, A. Nelson and C. O'Leary-Steele, *Nat. Prod. Rep.* 2008, **25**, 719. (h) W. R. J. D. Galloway, A. I. Llobet and D. R. Spring, *Nat. Commun.* 2010, **1**, 80. (i) S. Oh and S. B. Park, *Chem. Commun.* 2011, **47**, 12754.
- For reviews, see: G. Qiu, Q. Ding and J. Wu, *Chem. Soc. Rev.* 2013, **42**, 5257.
- For recent selected examples, see: (a) J. Sheng, C. Fan, Y. Ding, X. Fan and J. Wu, *Chem. Commun.* 2014, **50**, 4188. (b) G. Liu, H. Liu, S. Pu and J. Wu, *RSC Adv.* 2013, **3**, 10666. (c) Q. Xiao, J. Sheng, Q. Ding and J. Wu, *Eur. J. Org. Chem.* 2014, 217. (d) Q. Xiao, S. Ye and J. Wu, *Org. Lett.* 2012, **14**, 3430.
- (a) Z. Huo, H. Tomeba and Y. Yamamoto, *Tetrahedron Lett.* 2008, **49**, 5531. (b) H.-S. Yeom, J.-E. Lee and S. Shin, *Angew. Chem. Int. Ed.* 2008, **47**, 7040. (c) H.-S. Yeom, S. Kim and S. Shin, *Synlett* 2008, 924. (d) Q. Ding and J. Wu, *Adv. Synth. Catal.* 2008, **350**, 1850.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 5 (a) G. Qiu, Y. Hu, Q. Ding, Y. Peng and J. Wu, *Chem. Commun.* 2011, **47**, 9708. (b) G. Qiu, Q. Ding, H. Ren, Y. Peng and J. Wu, *Org. Lett.* 2010, **12**, 3975.
- 6 For selected examples, see: (a) C. Zhu, M. Yi, D. Wei, X. Chen, Y. Wu and X. Cui, *Org. Lett.* 2014, **16**, 1840. (b) M. Shang, S.-Z. Sun, H.-X. Dai and J.-Q. Yu, *J. Am. Chem. Soc.* 2014, **136**, 3354. (c) Q. Li, S.-Y. Zhang, G. He, Z. Ai, V. A. Nack and G. Chen, *Org. Lett.* 2014, **16**, 1764. (d) L. D. Trans, J. Roane and O. Daugulis, *Angew. Chem. Int. Ed.* 2013, **52**, 6043. (e) H. Zhao, Y. Shang and W. Su, *Org. Lett.* 2013, **15**, 5106. (f) A. John and K. M. Nicholas, *J. Org. Chem.* 2011, **76**, 4158. (g) H.-Y. Thu, W.-Y. Yu and C.-M. Che, *J. Am. Chem. Soc.* 2006, **128**, 9048. (h) X. Chen, X.-S. Hao, C. E. Goodhue and J.-Q. Yu, 2006, **128**, 6790. (i) D. Monguchi, T. Fujiwara, H. Furukawa and A. Mori, *Org. Lett.* 2009, **11**, 1607. (j) Q. Wang and S. L. Schreiber, *Org. Lett.* 2009, **11**, 5178. (k) J. Y. Kim, S. H. Cho, J. Joseph and S. Chang, *Angew. Chem. Int. Ed.* 2010, **49**, 9899. (l) S. H. Cho, J. Y. Kim, S. Y. Lee and S. Chang, *Angew. Chem. Int. Ed.* 2009, **48**, 9127. (m) Y. Li, Y. Xie, R. Zhang, K. Jin, X. Wang and C. Duan, *J. Org. Chem.* 2011, **76**, 5444. (n) S. Guo, B. Qian, Y. Xie, C. Xia and H. Huang, *Org. Lett.* 2011, **13**, 522 (o) H. Zhao, M. Wang, W. Su and M. Hong, *Adv. Synth. Catal.* 2010, **352**, 1301.